Biguanide derivative, a preparation method thereof, and a pharmaceutical composition containing the biguanide derivative as an active ingredient

A method of inhibiting of the proliferation of cancer cells, wherein the cancer is breast cancer, colorectal cancer, gastric cancer, liver cancer, lung cancer, blood cancer, prostate cancer, brain cancer, pancreatic cancer, ovarian cancer, or endometrial cancer, the method comprising:

• administering a therapeutically effective amount of a compound of Formula 1 below or a pharmaceutically acceptable salt to a subject in need thereof:
• wherein R1 is C5-12 aryl, or C1-12 alkyl unsubstituted or substituted with C5-12 aryl, and
• the aryl is unsubstituted or substituted with at least one non-hydrogen substituent selected from the group consisting of C1-4 alkyl, C1-4 alkoxy, hydroxyl, and halogen;
• R2 is hydrogen, or C1-12 alkyl unsubstituted or substituted with at least one non-hydrogen substituent selected from the group consisting of C3-10 cycloalkyl, C5-12 aryl, C5-12 heteroaryl, hydroxyl, halogen, and C1-4 alkoxycarbonyl, and
• the aryl and heteroaryl are unsubstituted or substituted with at least one non-hydrogen substituent selected from the group consisting of C1-4 alkyl, C1-4 alkoxy, hydroxyl, and halogen;
• R3 is hydrogen, C5-12 aryl, or C1-12 alkyl unsubstituted or substituted with at least one non-hydrogen substituent selected from the group consisting of C3-10 cycloalkyl, C5-12 aryl, C5-12 heteroaryl, hydroxyl, halogen, and C1-4 alkoxycarbonyl, and
• the aryl and heteroaryl are unsubstituted or substituted with at least one non-hydrogen substituent selected from the group consisting of C1-4 alkyl, C1-4 alkoxy, hydroxyl, and halogen;
• and
• R4 is C3-10 cycloalkyl, C1-12 alkoxy, C5-12 aryl, C5-12 heteroaryl, hydroxyl, halogen, or C1-12 alkyl unsubstituted or substituted with at least one non-hydrogen substituent selected from the group consisting of C3-10 cycloalkyl, C5-12 aryl, C5-12 heteroaryl, hydroxyl, halogen, and C1-4 alkoxycarbonyl, and
• the aryl and heteroaryl are unsubstituted or substituted with at least one non-hydrogen substituent selected from the group consisting of C1-4 alkyl, C1-4 alkoxy, hydroxyl, and halogen.